Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
1st December 2025

Company:	Chordia Therapeutics, Inc
Representative:	Chief Executive Officer Hiroshi Miyake
	(Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani

Notice Regarding the Recording of Non-Operating Income (Grant income)

Kanagawa Japan

1st December 2025 – Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") announced that it will record non-operating income (grant income) for the first quarter of the fiscal year ending August 31, 2026 (September 1, 2025 – November 30, 2025).

1. Details of the grant income

Chordia is currently conducting the research project titled "Non-clinical study of novel therapeutic agents for refractory tumors with RNA splicing mutations" under the "Research Project for Innovative Cancer Therapy Application" (hereinafter referred to as the "Project") of the Japan Agency for Medical Research and Development (hereinafter referred to as "AMED"), in collaboration with Kyoto University, a national university corporation.

The amount of the grant for the fiscal year ending March 2025 under the Project has now been finalized. Accordingly, Chordia will record 30,000 thousand yen as non-operating income (grant income) in the first quarter of the fiscal year ending August 31, 2026.

2. Impact on Business Results

The above non-operating income (grant income) will be recorded in the first quarter of the fiscal year ending August 31, 2026, and has already been incorporated into the business forecast for the fiscal year ending August 31, 2026, announced on October 14, 2025.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website: https://www.chordiatherapeutics.com/en/.